Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.49 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.49 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807947 | 0.91 | SLC28A3 (0.43) | P4HBPDIA4PDIA3CYP2D6THRB | |
| SCHEMBL7591908 | 0.88 | P4HB (0.48) | P4HBPDIA4PDIA3CYP2D6THRB | |
| SCHEMBL1726811 | 0.86 | HSD17B10 (0.46) | CYP2D6THRBHSD17B10TSHRMEN1 | |
| SCHEMBL1728220 | 0.85 | CYP2D6 (0.45) | P4HBPDIA4PDIA3CYP2D6THRB | |
| SCHEMBL14773376 | 0.85 | P4HB (0.53) | P4HBPDIA4PDIA3CYP2D6THRB | |
| SCHEMBL1726710 | 0.85 | P4HB (0.61) | P4HBPDIA4PDIA3CYP2D6THRB | |
| SCHEMBL8654501 | 0.85 | P4HB (0.61) | P4HBPDIA4PDIA3CYP2D6THRB | |
| SCHEMBL14773319 | 0.82 | HSD17B10 (0.53) | P4HBPDIA4PDIA3CYP2D6THRB | |
| SCHEMBL8376188 | 0.81 | P4HB (0.57) | P4HBPDIA4PDIA3CA2SLC28A3 | |
| SCHEMBL8376183 | 0.81 | P4HB (0.57) | P4HBPDIA4PDIA3CA2SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1609798-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-1609798-A9 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7566699-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1609798-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-0850948-B1 | Propiophenone derivatives and process for preparing the same | TANABE SEIYAKU CO (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6048842-A | ANTIDIABETIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0850948-A1 | Propiophenone derivatives and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | P4HB 661/4885PDIA4 2434/4885PDIA3 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.